Hisato Kawakami, MD, PhD, Kindai University, Osaka, Japan, discusses results from a blood-based biomarker analysis of the DELIVER trial which investigated nivolumab for advanced gastric cancer. 439 patients were included in the analysis. The aim of this analysis was to see if there was an association between these biomarkers and the treatment effects of nivolumab. Dr Kawakami also explains the Glasgow Prognostic Score (GPS) and talks on whether there was an association between the GPS and the nivolumab treatment effects. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.